Itajaí, Brazil Citywide Prevention Program using Ivermectin Significantly Reduced COVID-19 Infection, Hospitalization, and Mortality Rate

 FULL  ARTICLE  IS  HERE:

https://www.thegatewaypundit.com/2022/01/itajai-brazil-citywide-prevention-program-using-ivermectin-significantly-reduced-covid-19-infection-hospitalization-mortality-rate/

KEY POINTS:
A citywide prevention program using ivermectin as prophylaxis for COVID-19 was implemented in Itajaí, a southern city in Brazil in the state of Santa Catarina between July 2020 and December 2020.

According to this comprehensive study, the regular use of ivermectin as a prophylactic agent was associated with significantly reduced COVID-19 infection, hospitalization, and death rates.

The ivermectin non-users were two times more likely to die of COVID-19 than ivermectin users in the overall population analysis.

... for the 6,068 subjects (3,034 in each group), there were 44 hospitalizations among ivermectin users (1.6% hospitalization rate) and 99 hospitalizations (3.3% hospitalization rate) among ivermectin non-users, a 56% reduction in hospitalization rate.

When adjustment for variables was employed, the reduction in hospitalization rate was 67%

There were 25 deaths among ivermectin users (0.8% mortality rate) and 79 deaths among non-ivermectin users (2.6% mortality rate), a 68% reduction in mortality rate

... In this citywide ivermectin prophylaxis program, a large, statistically significant decrease in mortality rate was observed after the program began among the entire population of city residents.

When comparing subjects that used ivermectin regularly, non-users were two times more likely to die from COVID-19 while ivermectin users were 7% less likely to be infected with SARS-CoV-2

Although this study is not a randomized, double-blind, placebo-controlled clinical trial, the data were prospectively collected and resulted in a massive study sample that allowed adjustment for numerous confounding factors, thus strengthening the findings of the present study.

Due to the well-established, long-term safety profile of ivermectin, with rare adverse effects, the absence of proven therapeutic options to prevent death caused by COVID-19, and lack of effectiveness of vaccines in real-life all-cause mortality analyses to date ...

Cite this article as:
Kerr L, Cadegiani F A, Baldi F, et al. (January 15, 2022) Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching"